Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05228899 · ClinicalTrials.gov registry record · Phase 1
Zofin to Treat COVID-19 Long Haulers
A Phase 1 study of COVID-19, sponsored by ZEO ScientifiX.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT05228899 is a Phase 1 study of COVID-19 that has completed, run by ZEO ScientifiX. The registered enrollment target is 18 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05228899, a Phase 1 study of COVID-19, has completed, sponsored by ZEO ScientifiX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety and potential efficacy of Zofin administered intravenously in subjects experiencing prolonged symptoms (\> 6 weeks and \< 24 months) of COVID-19.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Zofin
Study Locations (4)
California
- NewportNativeMD - Newport Beach
- Assuta Family Medical Group - North Hollywood
Florida
- Innovation Clinical Trials - Miami
Texas
- United Memorial Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05228899
The ClinicalTrials.gov registry entry for NCT05228899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is ZEO ScientifiX, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05228899 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05228899 about?
NCT05228899 is a clinical study titled "Zofin to Treat COVID-19 Long Haulers". The purpose of this study is to assess the safety and potential efficacy of Zofin administered intravenously in subjects experiencing prolonged symptoms (\> 6 weeks and \< 24 months) of COVID-19.
What is the current status of trial NCT05228899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-04-14. Estimated completion is 2023-10-18.
What conditions does trial NCT05228899 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05228899?
The interventions under investigation include: Placebo (OTHER), Zofin (DRUG).
Who is sponsoring clinical trial NCT05228899?
This trial is sponsored by ZEO ScientifiX, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05228899 being conducted?
This trial has 4 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.